ATE513913T1 - Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen - Google Patents

Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen

Info

Publication number
ATE513913T1
ATE513913T1 AT06021369T AT06021369T ATE513913T1 AT E513913 T1 ATE513913 T1 AT E513913T1 AT 06021369 T AT06021369 T AT 06021369T AT 06021369 T AT06021369 T AT 06021369T AT E513913 T1 ATE513913 T1 AT E513913T1
Authority
AT
Austria
Prior art keywords
mage
immunogenic polypeptides
minigene
polypeptides encoded
nucleic acids
Prior art date
Application number
AT06021369T
Other languages
English (en)
Inventor
Neil Berinstein
Jim Tartaglia
John A Tine
Philippe Moingeon
Thierry Boon-Falleur
Der Bruggen Pierre Van
Original Assignee
Sanofi Pasteur Ltd
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd, Ludwig Inst Cancer Res filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of ATE513913T1 publication Critical patent/ATE513913T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
AT06021369T 2000-05-10 2001-05-07 Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen ATE513913T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20297000P 2000-05-10 2000-05-10
US20357800P 2000-05-11 2000-05-11
US24238800P 2000-10-20 2000-10-20

Publications (1)

Publication Number Publication Date
ATE513913T1 true ATE513913T1 (de) 2011-07-15

Family

ID=27394488

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01931269T ATE346925T1 (de) 2000-05-10 2001-05-07 Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
AT06021369T ATE513913T1 (de) 2000-05-10 2001-05-07 Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01931269T ATE346925T1 (de) 2000-05-10 2001-05-07 Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen

Country Status (11)

Country Link
US (3) US7851212B2 (de)
EP (2) EP1282702B1 (de)
AT (2) ATE346925T1 (de)
AU (3) AU2001258102B2 (de)
CA (1) CA2408328C (de)
CY (1) CY1107570T1 (de)
DE (1) DE60124899T2 (de)
DK (1) DK1282702T3 (de)
ES (1) ES2276788T3 (de)
PT (1) PT1282702E (de)
WO (1) WO2001085932A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131729C (en) * 1992-03-02 2008-02-12 Antonello Covacci Helicobacter pylori proteins useful for vaccines and diagnostics
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
JPH10502366A (ja) * 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクター・ピロリ抗原タンパク質調製品およびイムノアッセイ
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
ES2283012T3 (es) * 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
GB0023203D0 (en) * 2000-09-21 2000-11-01 Isis Innovation Vaccination method
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6096323A (en) * 1997-10-03 2000-08-01 The Regents Of The University Of California Vaccine against papillomatous digital dermatitis (PDD)
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
ES2294629T3 (es) 1998-05-01 2008-04-01 Novartis Vaccines And Diagnostics, Inc. Antigenos de neisseria y composiciones.
US6610306B2 (en) * 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
GB9928676D0 (en) * 1999-12-03 2000-02-02 Provalis Uk Ltd Pseudomonas aeruginosa antigens
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
WO2002094994A2 (en) * 2001-05-18 2002-11-28 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
JP2005506322A (ja) * 2001-08-31 2005-03-03 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉワクチン接種
WO2003047617A2 (en) 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
US20040156865A1 (en) * 2002-10-30 2004-08-12 The Board Of Regents For Oklahoma State University M. haemolytica outer membrane protein P1pE as a vaccine or vaccine component against shipping fever
US7794734B2 (en) * 2002-10-30 2010-09-14 The Board Of Regents For Oklahoma State University Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever
EP2338506A3 (de) * 2003-06-17 2011-10-12 Mannkind Corporation Kombinationen von tumor-assozierten antigenen zur behandlung von verschiedenen krebstypen
BRPI0413334A (pt) * 2003-09-05 2006-10-10 Sanofi Pasteur Ltd vetores de multiantìgenos para melanoma
US8329192B2 (en) * 2003-09-19 2012-12-11 Epitopix Llc Campylobacter polypeptides and methods of use
JP2008526760A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用
WO2007073768A1 (en) * 2005-12-23 2007-07-05 Vaxon Biotech Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof
WO2009033780A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of growth hormone-releasing factor and/or k237 as a therapeutic agents
CA2699012A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
ES2401904B1 (es) * 2011-07-19 2014-04-07 Consejo Superior De Investigaciones Científicas (Csic) Vectores recombinantes basados en el virus modificado de ankara (mva), con deleción en el gen c6l, como vacunas contra el vih/sida y otras enfermedades.
US10188715B2 (en) 2013-06-28 2019-01-29 Aquilon Cyl Sociedad Limitada Swine dysentery vaccine
RU2692647C2 (ru) * 2013-06-28 2019-06-25 Акилон Сил С.Л. Вакцина против дизентерии свиней
CN104232619A (zh) * 2014-09-12 2014-12-24 吉林大学 一种扩增游离dna的方法
GB201812647D0 (en) * 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4168062A (en) 1977-12-05 1979-09-18 Mccarthy Gerald F Automated goalie
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5378457A (en) 1981-12-24 1995-01-03 Virogenetics Corporation Interferon sensitive recombinant poxvirus vaccine
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5155020A (en) 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4882278A (en) 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
CA1288774C (en) 1985-01-07 1991-09-10 Deborah A. Eppstein 1,2-dialkoxy-w-trialkylammonium cationic surfactants
US4923808A (en) 1985-03-12 1990-05-08 Genentech, Inc. Method for identifying mutants secreting high levels of heterologous proteins
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5141742A (en) 1986-02-07 1992-08-25 Oncogen Vaccines against melanoma
US5015580A (en) 1987-07-29 1991-05-14 Agracetus Particle-mediated transformation of soybean plants and lines
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
JP3011939B2 (ja) 1987-03-02 2000-02-21 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 組換えミコバクテリア・ワクチン
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4956281A (en) 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US6699475B1 (en) 1987-09-02 2004-03-02 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
NL9020389A (nl) 1989-03-08 1991-12-02 Health Research Inc Systeem voor het in de gastheer selecteren van recombinant-pokkenvirussen.
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
EP1026253B2 (de) 1989-03-21 2012-12-19 Vical Incorporated Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE235558T1 (de) 1989-06-26 2003-04-15 Powderject Vaccines Inc Transformation von tierischen somatischen zellen mittels partikeln
WO1991011194A1 (en) 1990-01-24 1991-08-08 Biogen, Inc. Lfa-3 as a vaccine adjuvant
US5204243A (en) 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
CA2076753A1 (en) 1990-02-26 1991-08-27 Anthony J. Radford Shuttle plasmid for escherichia coli and mycobacteria
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
WO1992011361A1 (en) 1990-12-18 1992-07-09 The General Hospital Corporation Improved vaccines
WO1992011354A1 (en) 1990-12-18 1992-07-09 The General Hospital Corporation VIBRIO CHOLERAE STRAINS DEFECTIVE IN irgA EXPRESSION, AND CHOLERA VACCINES DERIVED THEREFROM
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
EP0575491B1 (de) 1991-03-07 2003-08-13 Virogenetics Corporation Gentechnologisch hergestellter stamm für impfstoffe
EP0584266B1 (de) 1991-05-06 2003-09-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
WO1992021376A1 (en) 1991-06-06 1992-12-10 Med Immune, Inc. Induction of ctl responses to foreign antigens expressed in mycobacteria
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
ATE295895T1 (de) 1992-03-11 2005-06-15 Powderject Vaccines Inc Genetischer impfstoff gegen den immunschwäche virus
AU671450B2 (en) 1992-03-20 1996-08-29 Baylor College Of Medicine A DNA transporter system and method of use
EP0636028B1 (de) 1992-04-03 2004-03-03 The Regents Of The University Of California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
ATE156710T1 (de) 1992-06-25 1997-08-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
AU4660893A (en) 1992-07-06 1994-01-31 President And Fellows Of Harvard College Deletion mutants as vaccines for cholera
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5405940A (en) 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
EP0658113B1 (de) 1992-08-31 2004-10-20 Ludwig Institute For Cancer Research Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5462871A (en) 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
DE69434469T2 (de) 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
AU683454B2 (en) 1993-02-22 1997-11-13 General Hospital Corporation, The Heterologous antigens in live cell vaccine strains
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
SG54115A1 (en) 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
ATE258434T1 (de) 1993-07-14 2004-02-15 Univ California Sich selbst zusammensetzendes polynukleotid- abgabesystem, das dendrimer-polykationen enthält
NZ271774A (en) 1993-08-06 1998-02-26 Cytel Corp Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH07190559A (ja) 1993-12-24 1995-07-28 Zexel Corp 積層型熱交換器
US5554724A (en) 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5851523A (en) 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5554506A (en) 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5686068A (en) 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5585461A (en) 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
EP1630229B1 (de) 1994-04-22 2013-04-03 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma Antigene
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US6060257A (en) 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US5997870A (en) 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
ES2154738T3 (es) 1994-10-03 2001-04-16 Us Gov Health & Human Serv Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
CA2201592A1 (en) 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
AU718772B2 (en) 1995-03-24 2000-04-20 Genzyme Corporation Adenovirus vectors for gene therapy
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0857176A1 (de) 1995-10-25 1998-08-12 Centocor B.V. VON HUMANEM EPITHELANTIGEN Ep-CAM ABGELEITETE PEPTIDE UND IHRE ANWENDUNG
EP0866721A4 (de) 1995-12-08 2003-06-04 Univ Alabama Birmingham Res Fo Adenovirale zielvektoren
US6083703A (en) 1996-02-09 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
FR2746110B1 (fr) 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
FR2748753B1 (fr) 1996-05-20 1998-08-14 Transgene Sa Nouveaux vecteurs adenoviraux pour la therapie genique
US20050136066A1 (en) 1996-06-12 2005-06-23 Yajun Guo Cellular vaccines and immunotherapeutics and methods for their preparation
US6805869B2 (en) 1996-06-12 2004-10-19 Shanghai Cp Guojian Pharmaceutical Co., Ltd. Cellular vaccines and immunotherapeutics and methods for their preparation
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
CA2261990A1 (en) 1996-07-25 1998-02-05 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
US6265215B1 (en) 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
CA2268353A1 (en) 1996-10-10 1998-04-16 Henrik Garoff Alphavirus-retrovirus vectors
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
EP1041152A1 (de) 1996-10-17 2000-10-04 Oxford Biomedica (UK) Limited Retrovirale Vektoren
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
WO1998017323A1 (en) 1996-10-23 1998-04-30 The Trustees Of The University Of Pennsylvania Improved vaccines
US7255862B1 (en) 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
AU5805798A (en) 1996-12-31 1998-07-31 Wistar Institute, The Recombinant adenoviral vector expressing antigens associated with colorectal tumors
CA2278931A1 (en) 1997-01-30 1998-08-06 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by a3-restricted cytotoxic lymphocytes, and uses therefor
AU7332198A (en) 1997-03-06 1998-09-22 Klaus Uberla Lentivirus based vector and vector system
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
AU7158398A (en) 1997-04-17 1998-11-11 Regents Of The University Of California, The Use of lentiviral vectors for antigen presentation in dendritic cells
NZ500740A (en) 1997-05-13 2001-02-23 Univ North Carolina Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV)
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
US6656734B1 (en) 1997-07-01 2003-12-02 Transgene S.A. Compositions for the delivery of polynucleotides to cells
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
DE69840962D1 (de) 1997-08-29 2009-08-20 Antigenics Inc Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
AU4110097A (en) 1997-08-29 1999-03-22 Sue-May Kang Method and apparatus for voluntary motor controlled convalescence
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
WO2000000600A2 (en) 1997-09-22 2000-01-06 Chang Lung Ji Lentiviral vectors, comprising modified major donor splice sites and major packaging signals
JP2001517433A (ja) 1997-09-24 2001-10-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非霊長類レンチウイルスベクターおよびパッケージングシステム
US6756038B1 (en) 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
AU1087299A (en) 1997-10-14 1999-05-03 Avant Immunotherapeutics, Inc. Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
AU1539399A (en) 1997-11-25 1999-06-15 Medical University Of South Carolina Inhibitors of nitric oxide synthase
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1037669A4 (de) 1997-12-12 2003-04-02 Cell Genesys Inc Therapeutische nutzung von lentiviralen vektoren
KR100824105B1 (ko) * 1998-02-05 2008-04-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신접종을 위한 융합 단백질 및 조성물의 제조를 위해사용되는 ｍａｇｅ 군으로부터의 종양 관련 항원 유도체 및이들을 암호화하고 있는 핵산 서열
CA2792479A1 (en) 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
WO1999046992A1 (en) 1998-03-20 1999-09-23 Genzyme Corporation Induction of immunity against tumor self-antigens
WO1999050292A1 (en) 1998-03-27 1999-10-07 The Secretary Of State For Defence Recombinant virus
US6171855B1 (en) 1998-05-28 2001-01-09 The Regents Of The University Of Michigan Vectors
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
WO2000020445A2 (en) * 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
EP1808180A3 (de) 1999-10-22 2010-12-22 Sanofi Pasteur Limited Modifiziertes GP 100 und Verwendung dafür
JP2003519197A (ja) 2000-01-05 2003-06-17 アヴェンティス パストゥール リミテッド 誘導物質および抗原で免疫する前に誘導物質で予備感作することによる、抗原に対する免疫応答の増強
US20030113919A1 (en) 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
AU2003228339A1 (en) 2002-03-20 2003-10-08 Aventis Pasteur, Inc. Prevention and treatment of disease using angiogenesis-and/or tumor antigens

Also Published As

Publication number Publication date
DE60124899T2 (de) 2007-08-16
EP1741782A3 (de) 2007-02-28
EP1282702B1 (de) 2006-11-29
WO2001085932A2 (en) 2001-11-15
DK1282702T3 (da) 2007-04-02
EP1282702A2 (de) 2003-02-12
AU5810201A (en) 2001-11-20
US20040033234A1 (en) 2004-02-19
AU2007200600A1 (en) 2007-03-08
EP1741782B1 (de) 2011-06-22
EP1741782A2 (de) 2007-01-10
CA2408328C (en) 2012-04-17
US20110250234A1 (en) 2011-10-13
US8257717B2 (en) 2012-09-04
EP1741782A8 (de) 2007-03-07
CY1107570T1 (el) 2013-03-13
EP1741782A9 (de) 2007-05-23
US7851212B2 (en) 2010-12-14
AU2007200600B2 (en) 2010-04-01
ATE346925T1 (de) 2006-12-15
ES2276788T3 (es) 2007-07-01
AU2001258102B2 (en) 2007-03-01
DE60124899D1 (de) 2007-01-11
WO2001085932A3 (en) 2002-09-06
PT1282702E (pt) 2007-02-28
CA2408328A1 (en) 2001-11-15
US20130216563A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
ATE513913T1 (de) Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DE69938302D1 (de) Neisseria meningitidis antigene und zusammenstellungen
WO2004003147A3 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
CY1111097T1 (el) Πρωτεϊνη δεσμευσης του υποδοχεα nogo
DK11789D0 (da) Rekombinante vaccinia-vira
ATE525388T1 (de) Hbv core-antigenpartikel, welche via peptidliganden, vielfältige immunogene komponenten gebunden haben
EA199800973A1 (ru) Полипептид белка-106 наружной мембраны moraxella catarrhalis, последовательность гена и их применение
ATE292685T1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
ATE364083T1 (de) Immunogene zusammensetzungen gegen eine helicobacterinfektion, verwendung von polypeptiden in diesen zusammensetzungen und nukleinsäurendie besagte polypeptide kodieren
ATE263836T1 (de) Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
WO2003038041A3 (en) Il-4 mutein proteins, antibodies, compositions, methods and uses
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
DE60042816D1 (de) T-helferzellen-epitope
ATE480620T1 (de) Neue pgc-1-isoformen und deren verwendungen
WO2003057821A3 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
ATE451461T1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
ATE354657T1 (de) Basb019 proteine und gene aus moraxella catarrhalis, antigene, antikörper, und verwendungen
WO2002062379A3 (en) Clostridium difficile vaccine
JP2004500829A5 (de)
WO2002010379A3 (en) Modified cea and uses thereof
WO2002059314A3 (en) A human melanoma associated antigen and uses therefor
ATE399205T1 (de) Immunogene polypeptide aus moraxella catarrhalis und deren verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties